Top-News

Curis News

Keine aktuellen Kursdaten verfügbar
WKN: 940909
ISIN: US2312691015
Typ: Aktie

Curis News

10.06.22 - PR Newswire
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress
Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress PR Newswire
06.06.22 - PR Newswire
Thinking about buying stock in Yumanity Therapeutics, Full Truck Alliance, Kanzhun, Curis, or Array Technologies?
Thinking about buying stock in Yumanity Therapeutics, Full Truck Alliance, Kanzhun, Curis, or Array Technologies? PR Newswire
04.06.22 - PR Newswire
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO)
Curis Announces Encouraging Emavusertib Data at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO) PR Newswire
02.06.22 - PR Newswire
Curis to Present at 2022 Jefferies Global Healthcare Conference
Curis to Present at 2022 Jefferies Global Healthcare Conference PR Newswire
12.05.22 - PR Newswire
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA)
Curis Announces Abstracts Accepted for Presentation at the European Hematology Association 2022 Congress (EHA) PR Newswire
05.05.22 - PR Newswire
Curis Reports First Quarter 2022 Financial Results and Business Update
Curis Reports First Quarter 2022 Financial Results and Business Update PR Newswire
28.04.22 - PR Newswire
Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022
Curis to Release First Quarter 2022 Financial Results and Hold Conference Call on May 5, 2022 PR Newswire
25.04.22 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS PR Newswire
11.04.22 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Curis, Inc. - CRIS PR Newswire
11.04.22 - PR Newswire
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948) PR Newswire
07.04.22 - PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
05.04.22 - PR Newswire
Curis to Present at 21st Annual Needham Virtual Healthcare Conference
Curis to Present at 21st Annual Needham Virtual Healthcare Conference PR Newswire
04.04.22 - PR Newswire
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948) PR Newswire
24.02.22 - PR Newswire
Curis Reports Fourth Quarter and Year End 2021 Financial Results
Curis Reports Fourth Quarter and Year End 2021 Financial Results - Presented positive updated data in Phase 1/2 TakeAim Leukemia study of CA-4948 Monotherapy in Targeted ...
17.02.22 - PR Newswire
Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022
Curis to Release Fourth Quarter 2021 Financial Results and Hold Conference Call on February 24, 2022 PR Newswire
20.01.22 - PR Newswire
Curis to Present at Upcoming Healthcare Conferences
Curis to Present at Upcoming Healthcare Conferences PR Newswire
07.01.22 - PR Newswire
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
06.01.22 - PR Newswire
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and MDS; and Initial Clinical Data from Phase 1 Study of CI-8993 in Patients with Relapsed or Refractory Solid Tumors
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of CA-4948 Monotherapy in Targeted Patients with Relapsed or Refractory AML and ...
03.01.22 - PR Newswire
Curis to Present at H.C. Wainwright BioConnect Conference
Curis to Present at H.C. Wainwright BioConnect Conference PR Newswire
15.12.21 - PR Newswire
Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF
Curis to be Added to the Nasdaq Biotechnology Index and the iShares Biotechnology ETF PR Newswire

Newssuche

Videos

18.04.24
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »